
Loading, please wait...

Loading, please wait...

Deprescribing in elderly patients has become an increasingly vital topic in modern geriatric care. As patients age, the burden of polypharmacy often outweighs the benefits of preventive medications. A recent analysis published in BMC Geriatrics explored this critical balance. The researchers examined whether stopping common preventive drugs impacts mortality or hospitalisation rates among frail adults. Interestingly, the findings suggest that reducing medication loads may not be as risky as previously feared.
The systematic review and meta-analysis involved over 33,000 participants across 15 different studies. Specifically, the team focused on medications like statins, antihypertensives, and antidiabetics. The results indicated that stopping these drugs did not increase the risk of major adverse cardiovascular events (MACE). Furthermore, the researchers observed no significant rise in all-cause mortality. Consequently, this data provides a level of reassurance for clinicians managing older patients with limited life expectancy.
Beyond mortality, the study also addressed safety outcomes such as falls and fractures. These events are leading causes of disability in the geriatric population. However, the analysis showed that deprescribing was not associated with a higher frequency of falls. Quality of life also remained stable throughout the observation periods. Nevertheless, stopping antihypertensive medications did lead to a slight increase in systolic blood pressure. Therefore, monitoring remains essential during the transition period.
Despite the encouraging results, the researchers highlighted a significant caveat regarding evidence certainty. They used the GRADE framework and found that the overall certainty was very low. This suggests that the true effect might differ from the current estimates. Consequently, the medical community needs more high-quality, randomized controlled trials. These studies should specifically target frail populations where the risk-benefit ratio is most narrow.
Currently, many frail, older adults receive multiple long-term medications despite uncertain clinical benefits. This practice often leads to adverse drug reactions and unnecessary healthcare costs. By carefully evaluating each prescription, doctors can improve patient safety and reduce the complexity of daily care. Ultimately, the goal of deprescribing is to align medication use with the patient’s current health status and personal goals.
Q1: Does deprescribing in elderly patients increase the risk of death?
Based on the latest analysis of 15 studies, stopping preventive medications in frail elderly adults was not associated with an increased risk of all-cause mortality.
Q2: Will stopping blood pressure medication lead to heart attacks in the frail?
The study found that deprescribing did not significantly increase the risk of major adverse cardiovascular events (MACE), although it did cause a slight rise in systolic blood pressure.
Q3: How does reducing medications affect the risk of falls?
The research suggests that deprescribing preventive drugs does not increase the risk of falls or fractures, which are common concerns in older populations.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A BMC Geriatrics study shows deprescribing preventive drugs in frail elderly doesn't increase mortality or falls, though evidence certainty remains very low...
6 months ago

As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today